ATE374199T1 - N-ä2-chlor-4-((6,7-dimethoxy-4- chinolyl)oxy)phenylü-n'-(5-methyl-3- isoxazolyl)harnstoffsalzin kristalliner form - Google Patents

N-ä2-chlor-4-((6,7-dimethoxy-4- chinolyl)oxy)phenylü-n'-(5-methyl-3- isoxazolyl)harnstoffsalzin kristalliner form

Info

Publication number
ATE374199T1
ATE374199T1 AT03756734T AT03756734T ATE374199T1 AT E374199 T1 ATE374199 T1 AT E374199T1 AT 03756734 T AT03756734 T AT 03756734T AT 03756734 T AT03756734 T AT 03756734T AT E374199 T1 ATE374199 T1 AT E374199T1
Authority
AT
Austria
Prior art keywords
quinolyl
isoxazolyl
dimethoxy
phenylü
oxy
Prior art date
Application number
AT03756734T
Other languages
English (en)
Inventor
Naoki Matsunaga
Satoshi Yoshida
Ayako Yoshino
Tatsuo Nakajima
Original Assignee
Kirin Brewery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32105192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE374199(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kirin Brewery filed Critical Kirin Brewery
Application granted granted Critical
Publication of ATE374199T1 publication Critical patent/ATE374199T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03756734T 2002-10-21 2003-10-21 N-ä2-chlor-4-((6,7-dimethoxy-4- chinolyl)oxy)phenylü-n'-(5-methyl-3- isoxazolyl)harnstoffsalzin kristalliner form ATE374199T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002306101 2002-10-21

Publications (1)

Publication Number Publication Date
ATE374199T1 true ATE374199T1 (de) 2007-10-15

Family

ID=32105192

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03756734T ATE374199T1 (de) 2002-10-21 2003-10-21 N-ä2-chlor-4-((6,7-dimethoxy-4- chinolyl)oxy)phenylü-n'-(5-methyl-3- isoxazolyl)harnstoffsalzin kristalliner form

Country Status (10)

Country Link
US (1) US7166722B2 (de)
EP (1) EP1559715B1 (de)
JP (1) JP3763414B2 (de)
AT (1) ATE374199T1 (de)
AU (1) AU2003301430A1 (de)
DE (1) DE60316590T2 (de)
DK (1) DK1559715T3 (de)
ES (1) ES2294317T3 (de)
PT (1) PT1559715E (de)
WO (1) WO2004035572A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253051T1 (de) * 1999-01-22 2003-11-15 Kirin Brewery Chinolinderivate und chinazolinderivate
WO2004006846A2 (en) 2002-07-15 2004-01-22 Exelixis, Inc. Receptor-type kinase modulators and methods of use
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
UA90691C2 (en) * 2004-09-29 2010-05-25 Баер Шеринг Фарма Акциенгезельшафт Process for the preparation of 4-{ 4-[({ [4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
US9037466B2 (en) * 2006-03-09 2015-05-19 Nuance Communications, Inc. Email administration for rendering email on a digital audio player
KR101733773B1 (ko) 2009-01-16 2017-05-10 엑셀리시스, 인코포레이티드 Ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US7998973B2 (en) * 2009-11-13 2011-08-16 Aveo Pharmaceuticals, Inc. Tivozanib and temsirolimus in combination
CA2812750C (en) 2010-09-27 2020-10-06 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
GEP20247677B (en) * 2011-02-10 2024-10-10 Exelixis Inc Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
CN102532116B (zh) * 2011-08-09 2015-01-21 武汉迈德森医药科技有限公司 抗肿瘤靶向治疗药物tivozanib的合成方法
CN104072492A (zh) * 2013-11-27 2014-10-01 苏州摩尔医药有限公司 一种抗肿瘤靶向治疗药物Tivozanib的合成方法
RS63136B9 (sr) 2016-09-13 2022-10-31 Kyowa Kirin Co Ltd Lekoviti sastav koji sadrži tivozanib
BR112021008606A2 (pt) 2018-11-05 2021-08-03 Aveo Pharmaceuticals, Inc. uso de tivozanibe para tratar indivíduos com câncer refratário
WO2023096651A1 (en) 2021-11-26 2023-06-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treating bile duct cancers with tivozanib
CN114213404B (zh) * 2021-12-27 2024-08-06 武汉九州钰民医药科技有限公司 Vegfr抑制剂替沃扎尼的合成工艺
WO2024095127A1 (en) 2022-10-31 2024-05-10 Pliva Hrvatska D.O.O. Solid state forms of tivozanib and process for preparation thereof
WO2024110606A1 (en) 2022-11-25 2024-05-30 Synthon B.V. A process for preparation of cabozantinib or tivozanib
CN117327061A (zh) * 2023-09-12 2024-01-02 武汉迈德森医药科技股份有限公司 一种替沃扎尼盐酸盐的制备方法及相关物质
CN117417336A (zh) * 2023-10-19 2024-01-19 武汉迈德森医药科技股份有限公司 一种替沃扎尼对甲苯磺酸盐的晶型及其制备方法和应用
WO2025120654A1 (en) * 2023-12-05 2025-06-12 Natco Pharma Limited An improved process for the preparation of tivozanib hydrochloride hydrate
WO2025220660A1 (ja) * 2024-04-15 2025-10-23 協和キリン株式会社 チボザニブ原薬およびその製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL205321B1 (pl) 1997-12-22 2010-04-30 Bayer Corp Zastosowanie podstawionych heterocyklicznych moczników do wytwarzania leku do hamowania kinazy raf, podstawione heterocykliczne moczniki oraz kompozycja farmaceutyczna je zawierająca
US7135466B2 (en) * 1999-12-24 2006-11-14 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives and drugs containing the same
HU230302B1 (hu) * 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
TWI324154B (de) 2001-04-27 2010-05-01 Kyowa Hakko Kirin Co Ltd
AU2003292838A1 (en) * 2002-12-27 2004-07-29 Kirin Beer Kabushiki Kaisha Therapeutic agent for wet age-related macular degeneration

Also Published As

Publication number Publication date
AU2003301430A1 (en) 2004-05-04
DK1559715T3 (da) 2007-12-27
US20060052415A1 (en) 2006-03-09
US7166722B2 (en) 2007-01-23
DE60316590T2 (de) 2008-06-19
JP3763414B2 (ja) 2006-04-05
EP1559715A4 (de) 2006-03-29
PT1559715E (pt) 2007-10-24
DE60316590D1 (en) 2007-11-08
WO2004035572A1 (ja) 2004-04-29
EP1559715A1 (de) 2005-08-03
ES2294317T3 (es) 2008-04-01
EP1559715B1 (de) 2007-09-26
JPWO2004035572A1 (ja) 2006-02-16

Similar Documents

Publication Publication Date Title
ATE374199T1 (de) N-ä2-chlor-4-((6,7-dimethoxy-4- chinolyl)oxy)phenylü-n'-(5-methyl-3- isoxazolyl)harnstoffsalzin kristalliner form
WO2004026863A8 (en) Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
SE0102300D0 (sv) Compounds
HU9600834D0 (en) Quinazoline derivatives
CY1110631T1 (el) Διαλυτοποιημενα δηλητηρια τοποϊσομερασης
BR0213242A (pt) Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto
MY146279A (en) Compounds affecting glucokinase
CY1112571T1 (el) 2,4-πυριμιδινοδιαμινες χρησιμες στην αντιμετωπιση νεοπλασματικων νοσων, φλεγμονωδων διαταραχων και διαταραχων του ανοσοποιητικου συστηματος
ATE344033T1 (de) Vinylphenyl-derivate als glk-aktivatoren
NO20051008L (no) Nye imidazolforbindelser som transformerende vekst faktor (TGF) inhibitorer
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
CY1111851T1 (el) Αρωματικες ενωσεις ως αντι-φλεγμονωδεις, ανοσορυθμιστικοι και αντι-πολλαπλασιαστικοι παραγοντες
BR0113590A (pt) 7-oxo-piridopirimidinas
DK1251846T3 (da) C4-Carbonattaxaner
ATE137501T1 (de) Benzazin-verbindungen und deren pharmazeutische verwendungen
DE69824313D1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
NO20023486L (no) Forbindelser av pyrroltypen, perapater inneholdende forbindelser samt deres anvendelse for behandling av cancer- ogvirale sykdommer
ATE137223T1 (de) Leukotrien-b4-antagonisten
NO20050573L (no) 4-'7-halo-2-quino (XA) linyloksy ! fenoksypropionsyrederivater som antineoplastiske midler
ES2089974B1 (es) Utilizacion de los derivados de 1-(4-)4-aril (o heteroaril)-1-piperazinil)-butil)-1-h-azol para la preparacion de medicamentos destinados al tratamiento de los trastornos de la secrecion gastrica.
ATE141605T1 (de) Thienotriazoldiazepinverbindungen und deren pharmazeutische anwendungen
BR0207102A (pt) Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença
RU2008127260A (ru) Производные хиназолинона в качестве антагонистов ваниллоидов
ATE139523T1 (de) Neue verbindungen und deren medizinale verwendung
RU2004112422A (ru) Роувастатин в преддеменционных состояниях

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties